Department of Surgery »  Faculty »  Adult Cardiothoracic Surgery »  Hassan Lemjabbar-Alaoui. Ph.D.

Hassan Lemjabbar-Alaoui, Ph.D.

Associate Professor
Department of Surgery

Contact Information

2340 Sutter Street N-224, Box 1724
University of California, San Francisco
San Francisco, CA 94143-1724
415-476-9303 Phone
Open Popup
  • University of Paris VII, B.S., Biology, 1988-1989
  • University of Paris VII, M.S.,  Molecular Biology and Immunology, 1989-1991
  • University of Paris VI, M.S., Biochemistry, 1991-1992
  • University of Paris VI, Post-Master University Diploma (DU), Clinical Pharmacokinetics and Therapeutics, 1992-1993
  • University of Paris XIII, Post-Master DE.A of Science, Medical and Biological Engineering, 1993-1994
  • University of Paris XII, Ph.D.,  Molecular and Cell Biology, 1994-1997
  • 1997-1998, Scientist, Naturalia Biologia. Paris, France
  • 1998-2001, Postdoctoral Researcher, Department of Anatomy, UCSF
  • Thoracic Oncology Program
  • Thoracic Oncology Laboratory
  • Member, UCSF Helen Diller Family Comprehensive Cancer Center
  • UCSF Department of Surgery
  • Biomarkers for early cancer detection
  • DNA repair mechanisms
  • Drug resistance mechanisms
  • Embryonic signaling pathways such as Wnt signaling
  • Novel targeted therapies
  • Role of the epidermal growth factor receptor (EGFR)
  • Sulf-1 and Sulf-2

Hassan Lemjabbar-Alaoui, Ph.D. is a biomedical scientist and Principal Investigator in the Thoracic Oncology Laboratory. Dr. Alaoui received his Ph.D. from the University of Paris XII.  Since receiving his Ph.D. from the University of Paris XII, he has focused his research work on deciphering the molecular mechanisms of lung cancer and other thoracic malignancies, and discovering novel targeted therapies and diagnostic biomarkers with clinical utility for the treatment of these diseases. Dr. Alaoui began these studies in 1997 as a postdoctoral fellow/Assistant Research Anatomist in Dr. Carol Basbaum's lab at UCSF, and continued them as an Assistant Professor of Anatomy at UCSF. 

Dr. Alaoui has also been the recipient of numerous awards including the prestigious National Institutes of Health/(NIH-NCI)/ U01 grant, the Doctors Cancer Foundation award, the Pfizer-CTI Research Program award, and the American Cancer Society. 

Dr. Alaoui's research is focused on elucidating diagnostic biomarkers and developing novel targeted therapies for treatment of lung cancer, mesothelioma and esophageal cancer. My lab seeks to gain a keen understanding of the molecular mechanisms underlying these diseases. Our projects include:

  1. Investigating the role of extracellular heparan sulfate degrading sulfatases (SULFs) in tumorigenesis, and finding novel ways to target them.
  2. Discovering novel blood biomarkers for early detection and stratification of thoracic malignancies.
  3. Elucidating the molecular mechanisms of multi-drug resistance in thoracic malignancies.
  4. Developing DNA repair inhibitors for thoracic malignancies, particularly small-molecule inhibitors, which hold great promise for damaging tumor cells.
  5. Adapting cAbl inhibitors, FDA-approved for the treatment of chronic myeloid leukemia (CML), for treatment of malignant mesothelioma, a devastating and currently incurable disease. 
  • 1U01CA168878-01 (National Institutes of Health/(NIH-NCI)): Extracellular Sulfatases As Novel Biomarkers For Early Detection of Cancer (08/16/2012-06/30/2017)
  • Consortium Collaborative Funds (National Institutes of Health/(NIH-NCI)): Proteomic and glycomic analysis of human brain and lung cancers. (07/01/2016-06/30/2017
Most recent publications from a total of 25
  1. Lui NS, Yang YW, van Zante A, Buchanan P, Jablons DM, Lemjabbar-Alaoui H. SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer. PLoS One. 2016; 11(2):e0148911. View in PubMed
  2. Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanan P. Lung cancer: Biology and treatment options. Biochim Biophys Acta. 2015 Dec; 1856(2):189-210. View in PubMed
  3. Lemjabbar-Alaoui H, McKinney A, Yang YW, Tran VM, Phillips JJ. Glycosylation alterations in lung and brain cancer. Adv Cancer Res. 2015; 126:305-44. View in PubMed
  4. Singer MS, Phillips JJ, Lemjabbar-Alaoui H, Wang YQ, Wu J, Goldman R, Rosen SD. SULF2, a heparan sulfate endosulfatase, is present in the blood of healthy individuals and increases in cirrhosis. Clin Chim Acta. 2015 Feb 2; 440:72-8. View in PubMed
  5. Kim JH, Chan C, Elwell C, Singer MS, Dierks T, Lemjabbar-Alaoui H, Rosen SD, Engel JN. Endosulfatases SULF1 and SULF2 limit Chlamydia muridarum infection. Cell Microbiol. 2013 Sep; 15(9):1560-71. View in PubMed
  6. Lui NS, van Zante A, Rosen SD, Jablons DM, Lemjabbar-Alaoui H. SULF2 expression by immunohistochemistry and overall survival in oesophageal cancer: a cohort study. BMJ Open. 2012; 2(6). View in PubMed
  7. Lemjabbar-Alaoui H, Sidhu SS, Mengistab A, Gallup M, Basbaum C. TACE/ADAM-17 phosphorylation by PKC-epsilon mediates premalignant changes in tobacco smoke-exposed lung cells. PLoS One. 2011; 6(3):e17489. View in PubMed
  8. Rosen SD, Lemjabbar-Alaoui H. Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate. Expert Opin Ther Targets. 2010 Sep; 14(9):935-49. View in PubMed
  9. Sidhu SS, Nawroth R, Retz M, Lemjabbar-Alaoui H, Dasari V, Basbaum C. EMMPRIN regulates the canonical Wnt/beta-catenin signaling pathway, a potential role in accelerating lung tumorigenesis. Oncogene. 2010 Jul 22; 29(29):4145-56. View in PubMed
  10. Uchimura K, Lemjabbar-Alaoui H, van Kuppevelt TH, Rosen SD. Use of a phage display antibody to measure the enzymatic activity of the Sulfs. Methods Enzymol. 2010; 480:51-64. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Hassan Lemjabbar-Alaoui, Ph.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.